Andrew Kelly, MD, PhD is a scientist on the International Medical Affairs Team at Foundation Medicine.
He received his medical degree from Temple University School of Medicine in Philadelphia,
Pennsylvania, USA. He also completed his PhD at Temple University in Cancer Biology. His research
has focused on genomic and epigenomic drivers of hematologic malignancies and identifying
molecularly-defined subtypes of sarcomas with differential therapy response. At Foundation Medicine,
Dr. Kelly provides scientific support at international molecular tumor boards and several active areas of
research.